Literature DB >> 9760193

Localization of a gene for incomplete X-linked congenital stationary night blindness to the interval between DXS6849 and DXS8023 in Xp11.23.

N T Bech-Hansen1, K M Boycott, K J Gratton, D A Ross, L L Field, W G Pearce.   

Abstract

Congenital stationary night blindness (CSNB) is a nonprogressive retinal disorder characterized by night blindness, nystagmus, myopia, a variable decrease in visual acuity, an abnormal electroretinographic response, and a disturbance in dark adaptation. Two forms of X-linked CSNB have been defined, complete CSNB in which rod function is extinguished, and incomplete CSNB in which rod function is reduced but not extinguished, as seen by electroretinography and dark adaptometry. In studying a large family of Mennonite ancestry, we have confirmed linkage between the locus (CSNB2) for incomplete CSNB and genetic markers in the Xp11 region. In particular, lod scores of 12.25 and 15.26 at zero recombination were observed between CSNB2 and the markers DXS573 and DXS255. Detailed analysis of critical recombinant chromosomes in this extended family have refined the minimal region for the CSNB2 locus to the interval between DXS6849 and DXS8023 in Xp11.23.

Entities:  

Mesh:

Year:  1998        PMID: 9760193     DOI: 10.1007/s004390050794

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  10 in total

1.  Genotype-phenotype correlation in British families with X linked congenital stationary night blindness.

Authors:  L E Allen; I Zito; K Bradshaw; R J Patel; A C Bird; F Fitzke; J R Yates; D Trump; A J Hardcastle; A T Moore
Journal:  Br J Ophthalmol       Date:  2003-11       Impact factor: 4.638

2.  ERGs in female carriers of incomplete congenital stationary night blindness (I-CSNB). A family report.

Authors:  Florence Rigaudière; Catherine Roux; Pierre Lachapelle; Serge G Rosolen; Pierre Bitoun; Annie Gay-Duval; Jean-François Le Gargasson
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

3.  Cav1.4 encodes a calcium channel with low open probability and unitary conductance.

Authors:  Clinton J Doering; Jawed Hamid; Brett Simms; John E McRory; Gerald W Zamponi
Journal:  Biophys J       Date:  2005-08-05       Impact factor: 4.033

Review 4.  Relevance of tissue specific subunit expression in channelopathies.

Authors:  Hartwig Seitter; Alexandra Koschak
Journal:  Neuropharmacology       Date:  2017-06-29       Impact factor: 5.250

Review 5.  Channeling studies in yeast: yeast as a model for channelopathies?

Authors:  Devin M Wolfe; David A Pearce
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 6.  Channelopathies: ion channel defects linked to heritable clinical disorders.

Authors:  R Felix
Journal:  J Med Genet       Date:  2000-10       Impact factor: 6.318

7.  Abnormalities of the scotopic threshold response correlated with gene mutation in X-linked retinoschisis and congenital stationary night blindness.

Authors:  Keith Bradshaw; Douglas Newman; Louise Allen; Anthony Moore
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379

Review 8.  Calcium channelopathies.

Authors:  Ricardo Felix
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 4.103

9.  Molecular profiling of complete congenital stationary night blindness: a pilot study on an Indian cohort.

Authors:  Sivasankar Malaichamy; Parveen Sen; Ramya Sachidanandam; Tharigopala Arokiasamy; Marie Elise Lancelot; Isabelle Audo; Christina Zeitz; Nagasamy Soumittra
Journal:  Mol Vis       Date:  2014-03-21       Impact factor: 2.367

10.  A Naturally Occurring Canine Model of Autosomal Recessive Congenital Stationary Night Blindness.

Authors:  Mineo Kondo; Gautami Das; Ryoetsu Imai; Evelyn Santana; Tomio Nakashita; Miho Imawaka; Kosuke Ueda; Hirohiko Ohtsuka; Kazuhiko Sakai; Takehiro Aihara; Kumiko Kato; Masahiko Sugimoto; Shinji Ueno; Yuji Nishizawa; Gustavo D Aguirre; Keiko Miyadera
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.